| Lung Cancer |
1 |
0.9 |
| Genomic Medicine |
0 |
0.77 |
| Arrhythmia |
0 |
0.71 |
| EGFR Inhibitor |
0 |
0.64 |
| Heart Failure (HF) |
0 |
0.61 |
| Epidermal Growth Factor Receptor |
0 |
0.48 |
| Heart |
0 |
0.43 |
| ALK Inhibitor |
0 |
0.41 |
| Non-Small Cell Lung Cancer |
0 |
0.39 |
| Anaplastic Lymphoma Kinase |
0 |
0.36 |
| Biologic Therapy |
0 |
0.35 |
| Cardiovascular Risk Management |
0 |
0.34 |
| Targeted Cancer Therapy |
0 |
0.27 |
| BRAF |
0 |
0.14 |
| Melanoma |
0 |
0.14 |
| Paroxysmal Supraventricular Tachycardia |
0 |
0.14 |
| Tyrosine Kinase Inhibitor |
0 |
0.12 |
| Long QT Syndrome |
0 |
0.1 |
| Tachycardia |
0 |
0.1 |
| Antineoplastic Drug |
0 |
0.08 |
| Small Cell Lung Cancer |
0 |
0.08 |
| Toxicology |
0 |
0.07 |
| Cancer |
0 |
0.05 |
| Cardiovascular disease |
0 |
0.05 |
| Clinical Guidelines |
0 |
0.05 |
| Drug Reaction |
0 |
0.05 |
| Lung |
0 |
0.05 |
| Tyrosine Kinase |
0 |
0.05 |